Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients

贝伐单抗 医学 肿瘤科 结直肠癌 药代动力学 内科学 癌胚抗原 混淆 危险系数 养生 比例危险模型 癌症 化疗 置信区间
作者
Sarah Lobet,Morgane Caulet,Gilles Paintaud,Nicolas Azzopardi,Céline Desvignes,Romain Chautard,Christophe Borg,Olivier Capitain,Aurélie Ferru,Olivier Bouché,Thierry Lecomte,David Ternant
出处
期刊:British Journal of Clinical Pharmacology [Wiley]
卷期号:90 (4): 976-986 被引量:2
标识
DOI:10.1111/bcp.15983
摘要

Aims The exposure‐response relationship of bevacizumab may be confounded by various factors, including baseline characteristics, time‐dependent target engagement and recursive relationships between exposure and response, requiring effective mitigation. This study aimed to investigate the exposure‐response relationships of bevacizumab in metastatic colorectal cancer (mCRC) patients while mitigating potential biases. Methods Bevacizumab pharmacokinetics was described using target‐mediated drug disposition modelling. Relationships between target kinetics, progression‐free (PFS) and overall (OS) survivals were assessed using joint pharmacokinetic and parametric hazard function models. Both prognostic‐driven and response‐driven potential biases were mitigated. These models evaluated the impact of increased antigen target levels, clearance and intensified dosing regimen on survival. Results Estimated target‐mediated pharmacokinetic parameters in 130 assessed patients were baseline target levels ( R 0 = 8.4 nM), steady‐state dissociation constant ( K SS = 10 nM) and antibody‐target complexes elimination constant ( k int = 0.52 day −1 ). The distribution of R 0 was significantly associated with increased baseline concentrations of carcinoembryonic antigen, circulating vascular endothelial growth factor and the presence of extrahepatic metastases. Unbound target levels ( R ) significantly influenced both progression and death hazard functions. Increasing baseline target levels and/or clearance values led to decreased bevacizumab unbound concentrations, increased R levels and shortened PFS and OS, while increasing bevacizumab dose led to decreased R and longer survival. Conclusion This study is the first to demonstrate the relationship between bevacizumab concentrations, target involvement and clinical efficacy by effectively mitigating potential sources of bias. Most of the target amount may be tumoural in mCRC. Future studies should provide a more in‐depth description of this relationship.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
2秒前
edfjiavi发布了新的文献求助10
3秒前
3秒前
3秒前
852应助dahuihui采纳,获得10
4秒前
HJJHJH发布了新的文献求助10
4秒前
lifan发布了新的文献求助10
4秒前
李健的小迷弟应助诸军则采纳,获得10
5秒前
6秒前
尊敬寒松发布了新的文献求助10
6秒前
8秒前
悦耳的涫发布了新的文献求助10
10秒前
积极斑马发布了新的文献求助10
11秒前
传奇3应助科研通管家采纳,获得10
12秒前
Lucas应助科研通管家采纳,获得10
12秒前
Hello应助科研通管家采纳,获得10
12秒前
斯文败类应助科研通管家采纳,获得10
12秒前
12秒前
aajhajkahna应助科研通管家采纳,获得10
13秒前
完美世界应助科研通管家采纳,获得10
13秒前
zz完成签到,获得积分10
13秒前
Tom发布了新的文献求助10
13秒前
顾矜应助科研通管家采纳,获得10
13秒前
研友_VZG7GZ应助科研通管家采纳,获得10
13秒前
13秒前
隐形曼青应助科研通管家采纳,获得10
13秒前
13秒前
13秒前
14秒前
脑洞疼应助辣椒油想躺平采纳,获得10
14秒前
酷波er应助zz采纳,获得10
15秒前
0201完成签到 ,获得积分10
16秒前
SADHIASK发布了新的文献求助10
17秒前
安安安安安完成签到 ,获得积分10
18秒前
19秒前
mrx完成签到,获得积分10
19秒前
19秒前
han发布了新的文献求助10
20秒前
淡定新烟完成签到,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
HYDROLYSE ACIDE DE QUELQUES DIOXASPIROCYCLANES 1314
Essentials of Carbohydrate Chemistry and Biochemistry, 4th Edition 800
Navigating Normative Orders. Interdisciplinary Perspectives 800
1 Peter and Christ's Descent to the Dead in Its Early Christian Reception 700
Organizational Behavior 510
Management and the Arts 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7746019
求助须知:如何正确求助?哪些是违规求助? 9293900
关于积分的说明 20222699
捐赠科研通 7325709
什么是DOI,文献DOI怎么找? 3308041
关于科研通互助平台的介绍 2459990
邀请新用户注册赠送积分活动 2319478